MSB 1.49% 99.5¢ mesoblast limited

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited...

  1. 87 Posts.
    lightbulb Created with Sketch. 31
    NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
99.5¢
Change
-0.015(1.49%)
Mkt cap ! $1.136B
Open High Low Value Volume
$1.02 $1.02 99.5¢ $2.005M 1.991M

Buyers (Bids)

No. Vol. Price($)
3 14424 99.5¢
 

Sellers (Offers)

Price($) Vol. No.
$1.00 63643 1
View Market Depth
Last trade - 16.10pm 19/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.